Legal & General Group
SGP

Legal & General Group’s SpyGlass Pharma SGP Stock Holding History

Legal & General Group’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1K Buy
+1,087
New +$23.6K ﹤0.01% 3039

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Legal & General Group's SGP Position: Q2 2026 in Review

Legal & General Group opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 1,087 shares worth $24.1K. The stake represents ﹤0.01% of the portfolio and ranks #3039 among its holdings.

43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Legal & General Group held 1,087 shares of SpyGlass Pharma worth $24.1K as of Q2 2026.
  • SpyGlass Pharma was a new Legal & General Group position in Q2 2026.
  • SpyGlass Pharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3039 holding.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.